Drug Profile
HDP 101
Alternative Names: HDP-101; HDP101-ATACLatest Information Update: 31 Mar 2024
Price :
$50
*
At a glance
- Originator Heidelberg Pharma AG
- Class Antineoplastics; Cyclic peptides; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 27 Mar 2024 HDP 101 receives Orphan Drug status for Multiple myeloma in USA
- 18 Mar 2024 Heidelberg Pharma efficacy data from a phase I/II trial in Multiple myeloma released by Heidelberg Pharma
- 09 Dec 2023 Efficacy, adverse events, pharmacokinetics and immunogenicity data from a phase I/IIa trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)